Chromocell Therapeutics (CHRO) स्टॉक

Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company’s patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced.